ergoline and Paralysis

ergoline has been researched along with Paralysis* in 2 studies

Other Studies

2 other study(ies) available for ergoline and Paralysis

Article	Year
Lisuride in parkinsonism. Annals of neurology, 1981, Volume: 9, Issue:1 Lisuride is a soluble ergolene derivative with endocrine effects similar to but more potent than those of bromocriptine. In nine subjects with idiopathic, postencephalitic, or drug-induced parkinsonism, lisuride at a dosage of 0.05 to 0.15 mg intravenously caused an immediate improvement in tremor, rigidity, akinesia, and postural deformity, but also caused chorea and orofacial dyskinesia. Improvement lasted 2 to 3 hours. Lisuride had little or no effect in a single patient with progressively supranuclear palsy. Oral lisuride therapy, 0.8 to 4.8 mg daily, had similar effects but occasionally caused reduced awareness and hallucinations. Topics: Administration, Oral; Aged; Benzimidazoles; Chorea; Domperidone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Ergolines; Female; Growth Hormone; Humans; Injections, Intravenous; Lisuride; Male; Middle Aged; Paralysis; Parkinson Disease; Parkinson Disease, Postencephalitic; Parkinson Disease, Secondary; Piperidines; Prolactin	1981
Effect of dopaminergic agonists and antagonists on in vivo cyclic nucleotide content: relation of guanosine 3':5'- monophosphate (cGMP) changes in cerebellum to behavior. The Journal of pharmacology and experimental therapeutics, 1979, Volume: 209, Issue:2 Topics: Animals; Antipsychotic Agents; Apomorphine; Cerebellum; Corpus Striatum; Cyclic AMP; Cyclic GMP; Dopamine; Dopamine Antagonists; Drug Interactions; Ergolines; Hydroxydopamines; Motor Activity; Paralysis; Piribedil; Rats	1979

Article

Year

Annals of neurology, 1981, Volume: 9, Issue:1

Lisuride is a soluble ergolene derivative with endocrine effects similar to but more potent than those of bromocriptine. In nine subjects with idiopathic, postencephalitic, or drug-induced parkinsonism, lisuride at a dosage of 0.05 to 0.15 mg intravenously caused an immediate improvement in tremor, rigidity, akinesia, and postural deformity, but also caused chorea and orofacial dyskinesia. Improvement lasted 2 to 3 hours. Lisuride had little or no effect in a single patient with progressively supranuclear palsy. Oral lisuride therapy, 0.8 to 4.8 mg daily, had similar effects but occasionally caused reduced awareness and hallucinations.

Topics: Administration, Oral; Aged; Benzimidazoles; Chorea; Domperidone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Ergolines; Female; Growth Hormone; Humans; Injections, Intravenous; Lisuride; Male; Middle Aged; Paralysis; Parkinson Disease; Parkinson Disease, Postencephalitic; Parkinson Disease, Secondary; Piperidines; Prolactin

1981

Effect of dopaminergic agonists and antagonists on in vivo cyclic nucleotide content: relation of guanosine 3':5'- monophosphate (cGMP) changes in cerebellum to behavior.

The Journal of pharmacology and experimental therapeutics, 1979, Volume: 209, Issue:2

Topics: Animals; Antipsychotic Agents; Apomorphine; Cerebellum; Corpus Striatum; Cyclic AMP; Cyclic GMP; Dopamine; Dopamine Antagonists; Drug Interactions; Ergolines; Hydroxydopamines; Motor Activity; Paralysis; Piribedil; Rats

1979